Abstract
Introduction: Whether immunohistochemical staining of programmed death ligand 1 (PD-L1) on cells of pleural effusion could be used to predict response to immunotherapy treatment has not been reported. Methods: We retrospectively enrolled patients who had undergone malignant pleural effusion drainage and had effusion cell block specimens from 2014 to 2016. Immunohistochemical staining for PD-L1 was performed with tumor cells, immune cells, and macrophages of all cell block specimens. Immunoactivity was scored as 0 for absence of staining and 1+ for faint, 2+ for moderate, and 3+ for intense membranous staining. Patients’ clinicopathological characteristics were also collected. Results: PD-L1 expression of pleural effusion tumor cells was associated with the PD-L1 expression of macrophages (p = 0.003) and immune cells (p < 0.001). However, the PD-L1 expression of immune cells was not associated with that of macrophages. The PD-L1 expression of tumor cells was correlated with sex (p = 0.012), smoking status (p = 0.032), and Eastern Cooperative Oncology Group performance status (p = 0.017). The PD-L1 expression of immune cells was associated with the overall survival of patients (p = 0.004). Conclusions: These results suggest that there might be an immune interaction between pleural effusion tumor cells and macrophages. The low intensity of PD-L1 expression in immune cells is associated with the poor survival of patients with lung cancer with malignant pleural effusion.
| Original language | English |
|---|---|
| Pages (from-to) | 447-453 |
| Number of pages | 7 |
| Journal | Journal of Thoracic Oncology |
| Volume | 13 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2018 |
Fingerprint
Keywords
- Immune cell
- Lung cancer
- Malignant pleural effusion
- PD-L1
- Tumor cell
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion. / Tseng, Yen Han; Ho, Hsiang Ling; Lai, Chiung Ru; Luo, Yung Hung; Tseng, Yen Chiang; Whang-Peng, Jacqueline; Lin, Yi hsuan; Chou, Teh Ying; Chen, Yuh Min.
In: Journal of Thoracic Oncology, Vol. 13, No. 3, 01.03.2018, p. 447-453.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion
AU - Tseng, Yen Han
AU - Ho, Hsiang Ling
AU - Lai, Chiung Ru
AU - Luo, Yung Hung
AU - Tseng, Yen Chiang
AU - Whang-Peng, Jacqueline
AU - Lin, Yi hsuan
AU - Chou, Teh Ying
AU - Chen, Yuh Min
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Introduction: Whether immunohistochemical staining of programmed death ligand 1 (PD-L1) on cells of pleural effusion could be used to predict response to immunotherapy treatment has not been reported. Methods: We retrospectively enrolled patients who had undergone malignant pleural effusion drainage and had effusion cell block specimens from 2014 to 2016. Immunohistochemical staining for PD-L1 was performed with tumor cells, immune cells, and macrophages of all cell block specimens. Immunoactivity was scored as 0 for absence of staining and 1+ for faint, 2+ for moderate, and 3+ for intense membranous staining. Patients’ clinicopathological characteristics were also collected. Results: PD-L1 expression of pleural effusion tumor cells was associated with the PD-L1 expression of macrophages (p = 0.003) and immune cells (p < 0.001). However, the PD-L1 expression of immune cells was not associated with that of macrophages. The PD-L1 expression of tumor cells was correlated with sex (p = 0.012), smoking status (p = 0.032), and Eastern Cooperative Oncology Group performance status (p = 0.017). The PD-L1 expression of immune cells was associated with the overall survival of patients (p = 0.004). Conclusions: These results suggest that there might be an immune interaction between pleural effusion tumor cells and macrophages. The low intensity of PD-L1 expression in immune cells is associated with the poor survival of patients with lung cancer with malignant pleural effusion.
AB - Introduction: Whether immunohistochemical staining of programmed death ligand 1 (PD-L1) on cells of pleural effusion could be used to predict response to immunotherapy treatment has not been reported. Methods: We retrospectively enrolled patients who had undergone malignant pleural effusion drainage and had effusion cell block specimens from 2014 to 2016. Immunohistochemical staining for PD-L1 was performed with tumor cells, immune cells, and macrophages of all cell block specimens. Immunoactivity was scored as 0 for absence of staining and 1+ for faint, 2+ for moderate, and 3+ for intense membranous staining. Patients’ clinicopathological characteristics were also collected. Results: PD-L1 expression of pleural effusion tumor cells was associated with the PD-L1 expression of macrophages (p = 0.003) and immune cells (p < 0.001). However, the PD-L1 expression of immune cells was not associated with that of macrophages. The PD-L1 expression of tumor cells was correlated with sex (p = 0.012), smoking status (p = 0.032), and Eastern Cooperative Oncology Group performance status (p = 0.017). The PD-L1 expression of immune cells was associated with the overall survival of patients (p = 0.004). Conclusions: These results suggest that there might be an immune interaction between pleural effusion tumor cells and macrophages. The low intensity of PD-L1 expression in immune cells is associated with the poor survival of patients with lung cancer with malignant pleural effusion.
KW - Immune cell
KW - Lung cancer
KW - Malignant pleural effusion
KW - PD-L1
KW - Tumor cell
UR - http://www.scopus.com/inward/record.url?scp=85042461374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042461374&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2017.10.034
DO - 10.1016/j.jtho.2017.10.034
M3 - Article
C2 - 29246835
AN - SCOPUS:85042461374
VL - 13
SP - 447
EP - 453
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 3
ER -